102 related articles for article (PubMed ID: 23408520)
1. A self-deletion lentiviral vector to reduce the risk of replication-competent virus formation.
Fang Y; Gong X; Xu M; Zeng F; Zhang J
J Gene Med; 2013 Feb; 15(2):102-12. PubMed ID: 23408520
[TBL] [Abstract][Full Text] [Related]
2. Self-inactivating lentiviral vectors with U3 and U5 modifications.
Iwakuma T; Cui Y; Chang LJ
Virology; 1999 Aug; 261(1):120-32. PubMed ID: 10441560
[TBL] [Abstract][Full Text] [Related]
3. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.
Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B
J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055
[TBL] [Abstract][Full Text] [Related]
4. Novel bovine lentiviral vectors based on Jembrana disease virus.
Metharom P; Takyar S; Xia HH; Ellem KA; Macmillan J; Shepherd RW; Wilcox GE; Wei MQ
J Gene Med; 2000; 2(3):176-85. PubMed ID: 10894263
[TBL] [Abstract][Full Text] [Related]
5. Hepatocyte-specific gene expression from integrated lentiviral vectors.
Nash KL; Jamil B; Maguire AJ; Alexander GJ; Lever AM
J Gene Med; 2004 Sep; 6(9):974-83. PubMed ID: 15352070
[TBL] [Abstract][Full Text] [Related]
6. Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1.
Chang LJ; Liu X; He J
Gene Ther; 2005 Jul; 12(14):1133-44. PubMed ID: 15750613
[TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus type 2 lentivirus vectors for gene transfer: expression and potential for helper virus-free packaging.
Arya SK; Zamani M; Kundra P
Hum Gene Ther; 1998 Jun; 9(9):1371-80. PubMed ID: 9650621
[TBL] [Abstract][Full Text] [Related]
8. Coordinate enhancement of transgene transcription and translation in a lentiviral vector.
Yilmaz A; Fernandez S; Lairmore MD; Boris-Lawrie K
Retrovirology; 2006 Feb; 3():13. PubMed ID: 16480517
[TBL] [Abstract][Full Text] [Related]
9. High levels of transgene expression following transduction of long-term NOD/SCID-repopulating human cells with a modified lentiviral vector.
Gao Z; Golob J; Tanavde VM; Civin CI; Hawley RG; Cheng L
Stem Cells; 2001; 19(3):247-59. PubMed ID: 11359950
[TBL] [Abstract][Full Text] [Related]
10. Reducing mobilization of simian immunodeficiency virus based vectors by primer complementation.
Grunwald T; Pedersen FS; Wagner R; Uberla K
J Gene Med; 2004 Feb; 6(2):147-54. PubMed ID: 14978768
[TBL] [Abstract][Full Text] [Related]
11. Chimeric HIV-1 and HIV-2 lentiviral vectors with added safety insurance.
Sachdeva G; D'Costa J; Cho JE; Kachapati K; Choudhry V; Arya SK
J Med Virol; 2007 Feb; 79(2):118-26. PubMed ID: 17177309
[TBL] [Abstract][Full Text] [Related]
12. Progress toward the genetic treatment of the beta-thalassemias.
Sadelain M; Lisowski L; Samakoglu S; Rivella S; May C; Riviere I
Ann N Y Acad Sci; 2005; 1054():78-91. PubMed ID: 16339654
[TBL] [Abstract][Full Text] [Related]
13. Hybrid HIV/MSCV LTR enhances transgene expression of lentiviral vectors in human CD34(+) hematopoietic cells.
Choi JK; Hoang N; Vilardi AM; Conrad P; Emerson SG; Gewirtz AM
Stem Cells; 2001; 19(3):236-46. PubMed ID: 11359949
[TBL] [Abstract][Full Text] [Related]
14. A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors.
Cockrell AS; Ma H; Fu K; McCown TJ; Kafri T
Mol Ther; 2006 Aug; 14(2):276-84. PubMed ID: 16516556
[TBL] [Abstract][Full Text] [Related]
15. Effects of viral strain, transgene position, and target cell type on replication kinetics, genomic stability, and transgene expression of replication-competent murine leukemia virus-based vectors.
Paar M; Schwab S; Rosenfellner D; Salmons B; Günzburg WH; Renner M; Portsmouth D
J Virol; 2007 Jul; 81(13):6973-83. PubMed ID: 17442710
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of HIV-1 replication by the Cre-loxP hammerhead ribozyme.
Habu Y; Miyano-Kurosaki N; Takeuchi H; Matsumoto N; Tamura Y; Takaku H
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):723-6. PubMed ID: 11563101
[TBL] [Abstract][Full Text] [Related]
17. Monitoring for potential adverse effects of prenatal gene therapy: genotoxicity analysis in vitro and on small animal models ex vivo and in vivo.
Themis M
Methods Mol Biol; 2012; 891():341-70. PubMed ID: 22648780
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense.
Mautino MR; Morgan RA
Gene Ther; 2002 Apr; 9(7):421-31. PubMed ID: 11938457
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system.
Chang LJ; Urlacher V; Iwakuma T; Cui Y; Zucali J
Gene Ther; 1999 May; 6(5):715-28. PubMed ID: 10505094
[TBL] [Abstract][Full Text] [Related]
20. Antisense RNA sequences targeting the 5' leader packaging signal region of human immunodeficiency virus type-1 inhibits viral replication at post-transcriptional stages of the life cycle.
Chadwick DR; Lever AM
Gene Ther; 2000 Aug; 7(16):1362-8. PubMed ID: 10981662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
